ATC Group: N02A Opioids

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N02A in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N02 Analgesics
3 N02A Opioids

Group N02A contents

Code Title
N02AA Natural opium alkaloids
N02AB Phenylpiperidine derivatives
N02AC Diphenylpropylamine derivatives
N02AD Benzomorphan derivatives
N02AE Oripavine derivatives
N02AF Morphinan derivatives
N02AG Opioids in combination with antispasmodics
N02AJ Opioids in combination with non-opioid analgesics
N02AX Other opioids

Active ingredients in N02A

Active Ingredient Description
Buprenorphine

Buprenorphine is an opioid partial agonist/antagonist which attaches itself to the μ (mu) and κ (kappa) receptors of the brain. Its activity in opioid maintenance treatment is attributed to its slowly reversible link with the μ receptors which, over a prolonged period, minimises the need of illicit opioids for patients with opioid dependence.

Butorphanol

Butorphanol is a morphinan-type synthetic agonist–antagonist opioid analgesic. Butorphanol is most closely structurally related to levorphanol. Butorphanol exhibits partial agonist and antagonist activity at the μ-opioid receptor, as well as partial agonist activity at the κ-opioid receptor (Ki = 2.5 nM; EC50 = 57 nM; Emax = 57%). Stimulation of these receptors on central nervous system neurons causes an intracellular inhibition of adenylate cyclase, closing of influx membrane calcium channels, and opening of membrane potassium channels. This leads to hyperpolarization of the cell membrane potential and suppression of action potential transmission of ascending pain pathways. Because of its κ-agonist activity, at analgesic doses butorphanol increases pulmonary arterial pressure and cardiac work. Additionally, κ-agonism can cause dysphoria at therapeutic or supertherapeutic doses; this gives butorphanol a lower potential for abuse than other opioid drugs.

Codeine and Ibuprofen

Ibuprofen is an NSAID which acts peripherally, inhibiting prostaglandin synthesis and the action of chemical mediators of pain. In humans, ibuprofen reduces inflammatory pain, swellings and fever. Codeine is a centrally acting weak analgesic. Codeine exerts its effect through μ opioid receptors, although codeine has low affinity for these receptors, and its analgesic effect is due to its conversion to morphine. The combination of a well tolerated peripheral analgesic with a centrally acting analgesic provides optimum pain relief with a lower potential for producing side effects.

Codeine and Paracetamol

The combination of paracetamol with codeine is a well-tolerated and effective analgesic. It consists of complementary active substances with different properties, but with common indication, the relief of pain. A special feature of the combination of paracetamol and codeine is the rapid onset of action after 10-20 minutes and the duration of action for 4-6 hours.

Dextromoramide

Dextromoramide is a powerful opioid analgesic approximately three times more potent than morphine but shorter acting. The main advantage of this drug is that it has a fast onset of action when taken orally, and has a high bioavailability which means that oral dosing produces almost as much effect as injection. It also has a relatively low tendency to cause constipation which is a common problem with opioid analgesics used for cancer pain relief, and tolerance to the analgesic effects develops relatively slowly compared to most other short-acting opioids.

Dextropropoxyphene

Propoxyphene, a synthetic opiate agonist, is structurally similar to methadone. Its general pharmacologic properties are those of the opiates as a group. The analgesic effect of propoxyphene is due to the d-isomer, dextropropoxyphene. It binds to the opiate receptors and leads to a decrease of the perception of pain stimuli. Propoxyphene possesses little to no antitussive activity and no antipyretic action.

Dihydrocodeine

Dihydrocodeine is a semisynthetic narcotic analgesic with a potency between morphine and codeine. It is also a centrally-acting anti-tussive. Dihydrocodeine works on the cough centre to lessen the incidence and intensity of coughing fits.

Dihydrocodeine and Paracetamol

The combination of dihydrocodeine and paracetamol is used to treat aches and pains, including headaches, migraines, muscle and joint pain, period pain and toothache.

Fentanyl

Fentanyl is a potent µ-opioid analgesic with rapid onset of analgesia and short duration of action. Its primary therapeutic actions are analgesia and sedation and is approximately 100-fold more potent than morphine as an analgesic. Secondary effects of fentanyl on central nervous system (CNS), respiratory and gastro-intestinal function are typical of opioid analgesics and are considered to be class effects.

Hydromorphone

Hydromorphone is an agonist of mu receptors. The pharmacological actions of hydromorphone and morphine do not differ significantly. Hydromorphone and related opioids produce their major effects on the central nervous system and bowel. Hydromorphone is indicated for the relief of severe pain in cancer.

Ketobemidone

Ketobemidone is a powerful synthetic opioid painkiller. Its effectiveness against pain is in the same range as morphine, and it also has some NMDA-antagonist properties imparted, in part, by its metabolite norketobemidone. This may make it useful for some types of pain that do not respond well to other opioids.

Levallorphan
Meptazinol

Meptazinol is a centrally acting analgesic belonging to the hexahydroazepine series, which has demonstrated mixed agonist and antagonist activity at opioid receptors. It is used for the short term treatment of moderate pain.

Morphine

Morphine is a narcotic analgesic obtained from opium. Morphine acts as an agonist at opiate receptors in the CNS particularly Mu and to a lesser extent Kappa receptors. Mu receptors are thought to mediate supraspinal analgesia, respiratory depression and euphoria, and Kappa receptors, spinal analgesia, miosis and sedation.

Nalbuphine

Nalbuphine is an opioid with kappa-agonistic and mu-antagonistic properties. Beside the essential agonistic (analgesic) effect nalbuphine has antagonistic effects of about a fourth of nalorfine and ten times of pentazocine.

Nicomorphine

Nicomorphine is the 3,6-dinicotinate ester of morphine. Nicomorphine is a strong opioid agonist analgesic two to three times as potent as morphine with a side effect profile similar to that of dihydromorphine, morphine, and diamorphine. The 3,6-diesters of morphine are drugs with more rapid and complete central nervous system penetration due to increased lipid solubility and other structural considerations.

Opium

Opium alkaloids (opioids and isoquinoline derivatives) induce constipation, euphoria, analgesia and sedation dependent on the dose and derivative. The constipating effect is caused by inhibition of the intestines' peristalsis.

Oxycodone

Oxycodone is a full opioid agonist with no antagonist properties. It has an affinity for kappa, mu and delta opioid receptors in the brain and spinal cord. Oxycodone is similar to morphine in its action. The therapeutic effect is mainly analgesic, anxiolytic, antitussive and sedative.

Oxycodone and Naloxone

Oxycodone and naloxone have an affinity for kappa, mu and delta opiate receptors in the brain, spinal cord and peripheral organs (e.g. intestine). Oxycodone acts as opioid-receptor agonist at these receptors and binds to the endogenous opioid receptors in the CNS. By contrast, naloxone is a pure antagonist acting on all types of opioid receptors. Naloxone counteracts opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.

Oxycodone and Paracetamol

Oxycodone and paracetamol combination is used to relieve moderate to severe pain. Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. The precise mechanism of the analgesic properties of acetaminophen is not established but is thought to involve central actions.

Oxymorphone

Oxymorphone is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxymorphone is analgesia. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and are thought to play a role in the analgesic effects of this drug.

Pentazocine

Pentazocine is an opioid, benzomorphan derivative analgesic with actions and uses similar to those of morphine. It has weak narcotic antagonist actions.

Pethidine

Pethidine is a synthetic opioid analgesic similar with similar actions to morphine. Like other opioids, pethidine binds to opioid receptors and exerts its principal pharmacological actions on the central nervous system where its analgesic and sedative effects are of particular therapeutic value. Pethidine also causes the release of histamine from mast cells resulting in a number of allergic-type reactions.

Phenazocine

Phenazocine is an opioid analgesic drug, which is related to pentazocine and has a similar profile of effects. Effects of phenazocine include analgesia and euphoria, also may include dysphoria and hallucinations at high doses, most likely due to action at κ-opioid and σ receptors. Phenazocine appears to be a much stronger analgesic with fewer side effects than pentazocine, probably due to a more favorable μ/κ binding ratio. Phenazocine is a much more potent analgesic than pentazocine and other drugs in the benzomorphan series, most probably due to the presence of an N-phenethyl substitution, which is known to boost μ-opioid activity in many classes of opioid analgesics. Consequently, phenazocine has four times the potency of morphine as an analgesic. Also it does not cause spasm of the sphincter of Oddi, making it more suitable than morphine for the treatment of biliary or pancreatic pain.

Piritramide

Piritramide is a pure µ-opioid receptor agonist, which has a slightly less analgesic potency than morphine. Analgesia results from activation of the µ-opioid receptors in the spine and the higher pain centres such as the thalamus and cerebral cortex, thereby raising the pain threshold and the sensitivity to pain.

Tapentadol

Tapentadol is a strong analgesic with µ-agonistic opioid and additional noradrenaline reuptake inhibition properties. Tapentadol exerts its analgesic effects directly without a pharmacologically active metabolite.

Tilidine

Tilidine is a synthetic opioid painkiller, for the treatment of moderate to severe pain, both acute and chronic. Tilidine itself is only a weak opioid, but is rapidly metabolised in the liver and gut to its active metabolite nortilidine and then to bisnortilidine. It is the (1S,2R)-isomer (dextilidine)12 that is responsible for its analgesic activity. Nortilidine binds to opiate receptors in the central and peripheral nervous systems and suppresses pain perception and transmission.

Tramadol

Tramadol is a centrally acting opioid analgesic. It is a non selective pure agonist at μ-, δ- and κ-opioid receptors with a higher affinity for the μ-receptor. Other mechanisms which may contribute to its analgesic effect are inhibition of neuronal reuptake of noradrenaline and enhancement of serotonin release. Tramadol has an antitussive effect. In contrast to morphine, analgesic doses of tramadol over a wide range have no respiratory depressant effect.

Tramadol and Dexketoprofen

Tramadol hydrochloride is a centrally acting synthetic opioid analgesic. It is a non-selective, partial agonist of μ-, δ- and κ-opioid receptors with a higher affinity for μ-receptors. Tramadol has an antitussive action. In contrast to morphine, analgesic doses of tramadol over a wide range have no respiratory depressant effect. Dexketoprofen is an analgesic, anti-inflammatory and antipyretic drug, which belongs to the non-steroidal anti-inflammatory group of drugs. The mechanism of action of non-steroidal antiinflammatory drugs is related to the reduction of prostaglandin synthesis by the inhibition of cyclooxygenase pathway.

Tramadol and Paracetamol

Tramadol is an opioid analgesic that acts on the central nervous system. Tramadol is a pure non selective agonists of the µ, δ, and κ opioid receptors with a higher affinity for the µ receptors. Tramadol has an antitussive effect. The precise mechanism of the analgesic properties of paracetamol is unknown and may involve central and peripheral effects. Tramadol/paracetamol is positioned as a step II analgesic in the WHO pain ladder and should be utilised accordingly by the physician.

Related product monographs

Title Information Source Document Type  
ABSTRAL Sublingual tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
BUTEC Transdermal patch Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
BUTRANS Transdermal system FDA, National Drug Code (US) MPI, US: SPL/PLR
CETVIO Film-coated tablet Health Products Regulatory Authority (ZA) MPI, Generic
CO-TIPOL Hard capsule Health Products Regulatory Authority (IE) MPI, EU: SmPC
CO-TIPOL Suppository Health Products Regulatory Authority (IE) MPI, EU: SmPC
CODANOL Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
COGESIC Tablet Marketing Authorisation Holder MPI, Generic
DILAUDID Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
DOLTREX Film-coated tablet Health Products Regulatory Authority (ZA) MPI, Generic
EMCOZIN Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
FENTANYL Solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
FENTORA Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
JURNISTA Prolonged-release tablet Marketing Authorisation Holder MPI, EU: SmPC
KADIAN Capsule extended-release FDA, National Drug Code (US) MPI, US: SPL/PLR
KAPAKE Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
LENIZAK Film-coated tablet Health Products Regulatory Authority (ZA) MPI, Generic
LYNLOR Capsule, hard Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
MATRIFEN Transdermal patch Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
MEDOTRAMOL Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
MEPTID Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
MEPTID Solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
MORPHGESIC Controlled release tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
MS CONTIN Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
MST CONTINUS Prolonged release granules for oral suspension Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
MST CONTINUS Prolonged-release tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
MYBULEN Capsule Health Products Regulatory Authority (ZA) MPI, Generic
NALPAIN Solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
NORSPAN Patch Medicines and Medical Devices Safety Authority (NZ) MPI, EU: SmPC
NUBAIN Solution for injection Health Products and Food Branch (CA) MPI, CA: SPM
NUCYNTA ER Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
OXYACT Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
OXYCODONE HYDROCHLORIDE 50 mg/ml Solution for injection or infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
OXYCODONE HYDROCHLORIDE Capsule FDA, National Drug Code (US) MPI, US: SPL/PLR
OXYCODONE HYDROCHLORIDE Oral solution FDA, National Drug Code (US) MPI, US: SPL/PLR
OXYCONTIN Film-coated, extended release tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
OXYNORM 10 mg/ml Solution for injection or infusion Υπουργείο Υγείας (CY) MPI, EU: SmPC
OXYNORM Capsule, hard Υπουργείο Υγείας (CY) MPI, EU: SmPC
OXYNORM Concentrate oral solution Υπουργείο Υγείας (CY) MPI, EU: SmPC
PAINAMOL PLUS Tablet Health Products Regulatory Authority (ZA) MPI, Generic
PALEXIA Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
PALEXIA Oral solution Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
PALEXIA SR Prolonged-release tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
PALLADONE Prolonged release capsule Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
PALLADONE Solution for injection or infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
PARACODIN Oral drops, solution Health Products Regulatory Authority (IE) MPI, EU: SmPC
PARACODIN Syrup Health Products Regulatory Authority (IE) MPI, EU: SmPC
PARACODIN Tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
PARCOTEN Tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
PECFENT Nasal spray, solution European Medicines Agency (EU) MPI, EU: SmPC
PROLATE Oral solution FDA, National Drug Code (US) MPI, US: SPL/Old
RELETRANS Transdermal patch Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
SEVREDOL Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
SKUDEXA Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
STATEX Oral Drops, Suppositories, Oral Syrup, Tablets Health Products and Food Branch (CA) MPI, CA: SPM
SUBOXONE Sublingual tablet European Medicines Agency (EU) MPI, EU: SmPC
TARGIN Prolonged-release tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
TARGINACT Prolonged release tablet Health Products Regulatory Authority (ZA) MPI, Generic
TARGINACT Prolonged-release tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
TEMGESIC Solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
TEMGESIC Sublingual tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
TRAMACET Film coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
TRAMAL Capsule, Solution for injection, Tablet Medicines and Medical Devices Safety Authority (NZ) MPI, EU: SmPC
TRANSTEC Transdermal patch Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
ULTRACET Coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
ULTRAM Coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
ZYDOL Soluble tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
ZYDOL Solution for injection or infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
ZYTRAM XL Controlled release tablet Health Products and Food Branch (CA) MPI, CA: SPM